Author of

• 14490

  +

  P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14515

    +

    P2.04-025 - Frequency of EGFR Mutation in Nsclc and Its Relationship with Clinicopathological Features: A Multicenter Asmo Trial (ID 603)

    09:30 - 09:30  |  Author(s): M. Aliustaoglu
    • Abstract
    • Slides

    Background:
    There has been important developments in NSCLC since the understanding of molecular pathways and the initiation of targeted treatments. The aim of the study is to find the EGFR mutation frequency and its correlation to survival and clinicopathological features.
    
    Methods:
    In this multicenter study, 827 NSCLC patients were included retrospectively to find out the EGFR mutation status with age, sex, performance status, histopathological diagnosis, smoking status and stage. Survival correlates were determined. The primary aim was to find out the EGFR mutation status with all of the features in the database. The secondary aim was to find out the effects of EGFR mutation status on survival with multivariate analysis.
    
    Results:
    The median age was 59 (24-87) years. Median follow-up period was 14 (2-117) months. 29,7% were female. 85,2% were stage IIIB-IV and 94% was adenocarcinoma. EGFR mutation frequency was 21,6% including exon 19 (62,3%). There was no correlation between mutational status and age, performance status and stage at diagnosis (p>0,05). However, there was a correlation between sex, smoking, and the metastatic area (p= 0.000, 0,000 ve 0.04 relatively). The frequency of mutation in female subjects was more pronounced in non-smokers/ex-smokers and less metastatic sites. Median progression-free survival was 9 months and overall survival was 20 months. The overall survival was 27 (SE:5; 95% CI 17-36) months in EGFR positive cases whereas 19 (SE:1; 95% CI 16-21) months in EGFR negative cases (p=0,008). The multivariate analysis showed good performance status, ealy stage diseaase and presence of EGFR mutation as a prognostic factor (p<0,05).
    
    Conclusion:
    Presence of EGFR mutation seems to be correlated with survival. The determination of EGFR mutation will lead the pathway for a better treatment outcome and individualised therapy.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.